Human papillomavirus–related genital disease in the immunocompromised host

Gormley, Rachel H.; Kovarik, Carrie L.

doi:10.1016/j.jaad.2010.12.049

Cited by 67 publications

(14 citation statements)

References 134 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In one study, 47% and 0 of patients had a complete response to topical 1% cidofovir and placebo respectively. Furthermore, 37% and 18% of patients had partial resolution with cidofovir and placebo respectively [17]. In children, off-label use of cidofovir has been used to control the growth of papillomas in recurrent respiratory papillomatosis (RRP), a benign, multi-focal neoplasm caused by HPV infection.…”

Section: Virucidal Therapymentioning

confidence: 99%

“…Interferon therapy can be topical, intralesional or systemic; however, topical interferon is not efficacious as it does not penetrate the stratum corneum [9,17]. …”

Section: Virucidal Therapymentioning

confidence: 99%

“…Intralesional and systemic interferon have shown efficacy in genital wart clearance, but are not first line given the associated side effects and exorbitant costs [17,23]. Intralesional interferon has demonstrated success rates up to 66% in clinical trials [24].…”

Section: Virucidal Therapymentioning

confidence: 99%

“…Intralesional interferon has demonstrated success rates up to 66% in clinical trials [24]. Local surgery and podophyllotoxin have been shown to increase the effectiveness of intralesional interferon [17]. One meta-analysis showed a recurrence rate of 21% with interferon versus 34% with placebo [25].…”

Section: Virucidal Therapymentioning

confidence: 99%

“…Side effects of systemic interferon are fever, headache, myalgia, myelosuppression, cardiotoxicity (arrhythmias, dilated cardiomyopathy and ischemic heart disease) and graft rejection in transplant patients. The risk of graft rejection is feared with intralesional interferon as well [17]. …”

Section: Virucidal Therapymentioning

confidence: 99%

See 4 more Smart Citations

Advancements in Pharmacotherapy for Noncancerous Manifestations of HPV

Kollipara

Ekhlassi

Downing

et al. 2015

JCM

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the most common sexually transmitted disease. Via infection of the basal epithelial cells, HPV causes numerous malignancies and noncancerous cutaneous manifestations. Noncancerous cutaneous manifestations of HPV, including common, plantar, plane, and anogenital warts, are among the most common reasons for an office visit. Although there are various therapies available, they are notoriously difficult to treat. HPV treatments can be grouped into destructive (cantharidin, salicylic acid), virucidal (cidofovir, interferon-α), antimitotic (bleomycin, podophyllotoxin, 5-fluorouracil), immunotherapy (Candida antigen, contact allergen immunotherapy, imiquimod) or miscellaneous (trichloroacetic acid, polyphenon E). The mechanism of action, recent efficacy data, safety profile and recommended regimen for each of these treatment modalities is discussed.

show abstract

Section: Virucidal Therapymentioning

confidence: 99%

“…Interferon therapy can be topical, intralesional or systemic; however, topical interferon is not efficacious as it does not penetrate the stratum corneum [9,17]. …”

Section: Virucidal Therapymentioning

confidence: 99%